Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy

Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy

Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jorge A. Roacho-Pérez, Elsa N. Garza-Treviño, Paulina Delgado-Gonzalez, Zuca G-Buentello, Juan Luis Delgado-Gallegos, Christian Chapa-Gonzalez, Margarita Sánchez-Domínguez, Celia N. Sánchez-Domínguez, Jose Francisco Islas
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
pancreatic cancer
molecular markers
target therapy
nanomedicine
Science
Q
Acceso en línea:https://doaj.org/article/205d352e61ba491d8955bb9be25ba703
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/205d352e61ba491d8955bb9be25ba703

Ejemplares similares